This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Multitude Therapeutics


Multitude Therapeutics is a clinical-stage biotech developing FIC/BIC ADCs by its unparalleled target and antibody discovery MabArray technology, a high-throughput screening of live cells for acquisition of new targets and lead antibodies(Sci. Adv. 2020), combined with a proprietary T1000-exatecan linker payload platform(Cancer Discov. 2023). This powerful synergy enabled Multitude to build an atlas of ADCs that has the potential to treat malignancies with high unmet medical needs.